JP2003521916A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003521916A5 JP2003521916A5 JP2001557921A JP2001557921A JP2003521916A5 JP 2003521916 A5 JP2003521916 A5 JP 2003521916A5 JP 2001557921 A JP2001557921 A JP 2001557921A JP 2001557921 A JP2001557921 A JP 2001557921A JP 2003521916 A5 JP2003521916 A5 JP 2003521916A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- ige
- dog
- described method
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 description 17
- 239000008194 pharmaceutical composition Substances 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 241000282465 Canis Species 0.000 description 4
- 230000027455 binding Effects 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 210000003651 basophil Anatomy 0.000 description 2
- 210000003630 histaminocyte Anatomy 0.000 description 2
- 102220013004 rs7811324 Human genes 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000009870 specific binding Effects 0.000 description 2
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000003182 parenteral nutrition solution Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17962900P | 2000-02-01 | 2000-02-01 | |
| US60/179,629 | 2000-02-01 | ||
| US09/592,998 | 2000-06-12 | ||
| US09/592,998 US6504013B1 (en) | 2000-02-01 | 2000-06-12 | Canine allergy therapeutic recombinant chimeric anti-IgE monoclonal antibody |
| PCT/US2001/002924 WO2001057090A1 (en) | 2000-02-01 | 2001-01-30 | Canine allergy therapeutic recombinant chimeric anti-ige monoclonal antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2003521916A JP2003521916A (ja) | 2003-07-22 |
| JP2003521916A5 true JP2003521916A5 (enExample) | 2008-03-27 |
| JP4605973B2 JP4605973B2 (ja) | 2011-01-05 |
Family
ID=26875491
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2001557921A Expired - Fee Related JP4605973B2 (ja) | 2000-02-01 | 2001-01-30 | イヌのアレルギー治療用の組換えキメラ抗−ＩｇＥモノクローナル抗体 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US6504013B1 (enExample) |
| EP (1) | EP1254180B1 (enExample) |
| JP (1) | JP4605973B2 (enExample) |
| AU (1) | AU2001233102A1 (enExample) |
| DE (1) | DE60127237T2 (enExample) |
| WO (1) | WO2001057090A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7393529B2 (en) * | 1998-04-09 | 2008-07-01 | Idexx Laboratories, Inc. | Methods and compositions for inhibiting binding of IgE to a high affinity receptor |
| CA2429372A1 (en) * | 2001-01-03 | 2002-08-29 | Heska Corporation | Detection of allergen-specific ige |
| EP1485126A4 (en) * | 2001-12-21 | 2007-03-21 | Idexx Lab Inc | DOG IMMUNOGLOBULIN VARIABLE DOMAINS, DOG ANTIBODIES, AND METHOD FOR THEIR PRODUCTION AND USE |
| JP2006519763A (ja) * | 2002-11-08 | 2006-08-31 | アブリンクス エン．ヴェー． | 治療用ポリペプチドの投与法およびそのためのポリペプチド |
| US20100003253A1 (en) * | 2002-11-08 | 2010-01-07 | Ablynx N.V. | Single domain antibodies directed against epidermal growth factor receptor and uses therefor |
| US9320792B2 (en) | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| US20060034845A1 (en) * | 2002-11-08 | 2006-02-16 | Karen Silence | Single domain antibodies directed against tumor necrosis factor alpha and uses therefor |
| ATE517922T1 (de) * | 2002-11-08 | 2011-08-15 | Ablynx Nv | Stabilisierte einzel-domänen-antikörper in einer pharmazeutischen zusammensetzung ausgestaltet für inhalation |
| GB0304576D0 (en) | 2003-02-28 | 2003-04-02 | Lonza Biologics Plc | Protein a chromatography |
| WO2005095967A1 (en) * | 2004-03-23 | 2005-10-13 | Quidel Corporation | Hybrid phase lateral flow assay |
| US20090111702A1 (en) * | 2004-04-06 | 2009-04-30 | Mount Sinai School Of Medicine Office Of Industrial Liason | Methods of determining allergen response using microarray immunoassay techniques |
| JP2006151880A (ja) * | 2004-11-30 | 2006-06-15 | Asahi Breweries Ltd | 抗イヌＩｇＥモノクローナル抗体、その製造法および用途 |
| ES2797480T3 (es) | 2005-03-11 | 2020-12-02 | Wyeth Llc | Un procedimiento de cromatografía de reparto débil |
| JP2007172129A (ja) * | 2005-12-20 | 2007-07-05 | Sony Corp | 不揮発性メモリアクセス制御装置および不揮発性メモリ制御システム |
| US9388236B2 (en) | 2007-07-09 | 2016-07-12 | Nestec Sa | Methods for reducing allergies caused by environmental allergens |
| US8454953B2 (en) * | 2007-07-09 | 2013-06-04 | Nestec Sa | Methods for reducing allergies caused by environmental allergens |
| ES2910305T3 (es) | 2010-08-19 | 2022-05-12 | Zoetis Belgium S A | Anticuerpos anti-NGF y su uso |
| US9546219B2 (en) | 2012-02-08 | 2017-01-17 | North Carolina State University | Treatment of allergic diseases with recombinant antibodies |
| JP6199054B2 (ja) * | 2013-03-19 | 2017-09-20 | 公益財団法人かずさＤｎａ研究所 | 抗イヌＩｇＥモノクローナル抗体並びに抗イヌＩｇＥモノクローナル抗体の重鎖可変領域及び軽鎖可変領域 |
| WO2018089335A1 (en) | 2016-11-09 | 2018-05-17 | North Carolina State University | Treatment of allergic diseases with chimeric protein |
| WO2019183437A1 (en) | 2018-03-23 | 2019-09-26 | North Carolina State University | Methods and compositions for antibody to high affinity receptor for ige |
| CN109143137B (zh) * | 2018-06-14 | 2020-09-29 | 国电南瑞科技股份有限公司 | 一种发电机pmu装置测量精度提升方法 |
| US20230148946A1 (en) * | 2020-03-27 | 2023-05-18 | Aquavit Pharmaceuticals, Inc. | Methods of detecting allergic reactions in subjects using microchannel delivery devices |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5422258A (en) | 1987-12-31 | 1995-06-06 | Tanox Biosystems, Inc. | Methods for producing high affinity anti-human IgE-monoclonal antibodies which binds to IgE on IgEabearing B cells but not basophils |
| DE122006000007I2 (de) | 1987-12-31 | 2008-03-27 | Tanox Inc | -tragenden b-lymphocyten befinden. |
| US5449760A (en) | 1987-12-31 | 1995-09-12 | Tanox Biosystems, Inc. | Monoclonal antibodies that bind to soluble IGE but do not bind IGE on IGE expressing B lymphocytes or basophils |
| JP2837240B2 (ja) * | 1990-06-07 | 1998-12-14 | 財団法人化学及血清療法研究所 | イヌ免疫グロブリンγ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体 |
| JP2811096B2 (ja) * | 1989-09-30 | 1998-10-15 | 財団法人化学及血清療法研究所 | イヌ免疫グロブリンκ鎖の定常領域をコードする遺伝子断片およびマウス×イヌキメラ抗体 |
| JP2811089B2 (ja) * | 1989-08-25 | 1998-10-15 | 財団法人化学及血清療法研究所 | イヌ×マウスヘテロハイブリドーマおよびイヌ免疫グロブリンλ鎖の定常領域をコードする遺伝子断片 |
| ATE233813T1 (de) * | 1991-08-14 | 2003-03-15 | Genentech Inc | Veränderte immunglobuline für spezifische fc- epsilon rezeptoren |
| US5965709A (en) | 1991-08-14 | 1999-10-12 | Genentech, Inc. | IgE antagonists |
| SE9102808L (sv) | 1991-09-26 | 1993-03-27 | Lars T Hellman Inst F Immunolo | Vaccin, foer humant bruk, vars avsedda effekt aer att lindra symptomen eller foerhindra uppkomsten av ige-medierade allergiska reaktioner |
| WO1994020533A1 (en) | 1993-03-11 | 1994-09-15 | Tanox Biosystems, Inc. | PEPTIDES REPRESENTING ANTIGENIC EPITOPES OF IgE PRESENT ON B CELL BUT NOT BASOPHIL SURFACE |
| US5629415A (en) | 1994-11-09 | 1997-05-13 | Merck & Co., Inc. | DNA encoding canine immunoglobulin E |
| AU1146897A (en) | 1995-12-08 | 1997-06-27 | Idexx Laboratories, Inc. | Methods and compositions concerning allergy in dogs |
| US5945294A (en) | 1996-11-26 | 1999-08-31 | Heska Corporation | Method to detect IgE |
| US6060326A (en) | 1997-04-07 | 2000-05-09 | Heska Corporation | Method to detect canine IgE and kit therefor |
| US5994511A (en) | 1997-07-02 | 1999-11-30 | Genentech, Inc. | Anti-IgE antibodies and methods of improving polypeptides |
| ES2234180T3 (es) | 1998-04-09 | 2005-06-16 | Idexx Laboratories, Inc. | Proteinas de fijacion especifica para el tratamiento de la alergia canina. |
| TWI227241B (en) | 1998-06-20 | 2005-02-01 | United Biomedical Inc | IgE-CH3 domain antigen peptide, peptide conjugate containing the same, and pharmaceutical composition for treating allergies containing the peptide conjugate |
-
2000
- 2000-06-12 US US09/592,998 patent/US6504013B1/en not_active Expired - Fee Related
-
2001
- 2001-01-30 DE DE60127237T patent/DE60127237T2/de not_active Expired - Lifetime
- 2001-01-30 WO PCT/US2001/002924 patent/WO2001057090A1/en not_active Ceased
- 2001-01-30 EP EP01905198A patent/EP1254180B1/en not_active Expired - Lifetime
- 2001-01-30 AU AU2001233102A patent/AU2001233102A1/en not_active Abandoned
- 2001-01-30 JP JP2001557921A patent/JP4605973B2/ja not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2003521916A5 (enExample) | ||
| Andersen et al. | Elimination of erroneous results in flow cytometry caused by antibody binding to Fc receptors on human monocytes and macrophages | |
| ATE454124T1 (de) | Rekombinante anti-cd30-antikörper und deren verwendungen | |
| Gevaert et al. | Organization of secondary lymphoid tissue and local IgE formation to Staphylococcus aureus enterotoxins in nasal polyp tissue | |
| DK0930365T3 (da) | Bindingsdomæner i Serrate-protein | |
| WO2005000244A3 (en) | Methods and compositions for treating rheumatoid arthritis | |
| KR960704576A (ko) | CD40에 대한 항체(Antibodies to CD40) | |
| JP2004517611A5 (enExample) | ||
| RU2012133522A (ru) | Новое применение соединений ил-1 бета | |
| NO20051048L (no) | Terapeutisk humant anti-IL-1R1 monoklonalt antistoff | |
| AU2019312565B2 (en) | Anti-MICA/B antibodies that block MICA/B shedding and methods of use | |
| RU2007139452A (ru) | СПОСОБЫ И КОМПОЗИЦИИ ДЛЯ МОДУЛИРОВАНИЯ ГИПЕРСТАБИЛИЗИРОВАННОГО c-met | |
| JP2004510752A5 (enExample) | ||
| DE69334266D1 (de) | Therapeutische Zusammensetzungen aus Antikorper und Antisens Nukleinsäuren gegen Serrate | |
| NZ712762A (en) | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r | |
| CA2624935A1 (en) | Anti-myostatin antibodies | |
| JP2018529635A5 (enExample) | ||
| CA2417432A1 (en) | Modified polypeptides stabilized in a desired conformation and methods for producing same | |
| Seppälä et al. | Mouse Ig coded by VH families S107 or J606 bind to protein A. | |
| JP2020527152A5 (enExample) | ||
| Rice et al. | Cross-reactivity of monoclonal antibodies against peptide 277–294 of rainbow trout CYP1A1 with hepatic CYP1A among fish | |
| JP2002538771A5 (enExample) | ||
| JP2025087764A5 (enExample) | ||
| RU2206614C2 (ru) | Моноклональное антитело к сд23 человека и его использование | |
| JP3591782B2 (ja) | 熱処理されたＩｇＭ抗体製剤 |